• English
    • Ελληνικά
  • English 
    • English
    • Ελληνικά
  • Login
Browsing by Subject 
  •   Home
  • Browsing by Subject
  •   Home
  • Browsing by Subject
JavaScript is disabled for your browser. Some features of this site may not work without it.

Browsing by Subject "Leukopenia"

  • 0-9
  • Α
  • Β
  • Γ
  • Δ
  • Ε
  • Ζ
  • Η
  • Θ
  • Ι
  • Κ
  • Λ
  • Μ
  • Ν
  • Ξ
  • Ο
  • Π
  • Ρ
  • Σ
  • Τ
  • Υ
  • Φ
  • Χ
  • Ψ
  • Ω
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Sort by:

Order:

Results:

Now showing items 1-20 of 48

  • title
  • submit date
  • accessioned date
  • ascending
  • descending
  • 5
  • 10
  • 20
  • 40
  • 60
  • 80
  • 100
    • Article  

      Adjuvant chemotherapy using CPT-11, leucovorin plus bolus 5-fluorouracil and radiotherapy in patients with rectal cancer. A feasibility study 

      Kalofonos, H. P.; Kardamakis, D.; Bamias, A. T.; Skarlos, Dimosthenis V.; Papakostas, P.; Bafaloukos, Dimitrios; Sakantamis, A.; Pavlidis, Nicholas; Fountzilas, George (2003)
      Background: The addition of CPT-11 to 5FU/leucovorin resulted in survival benefit in patients with advanced colorectal cancer suggesting that this combination could be used successfully in the adjuvant setting. We studied ...

    • Article  

      Adjuvant Cytotoxic and Endocrine Therapy in Pre- and Postmenopausal Patients with Breast Cancer and One to Nine Infiltrated Nodes: Five-Year Results of the Hellenic Cooperative Oncology Group Randomized HE 10/92 Study 

      Fountzilas, George; Stathopoulos, G. P.; Kouvatseas, G.; Polychronis, A.; Klouvas, G. D.; Samantas, E.; Zamboglou, N.; Kyriakou, K.; Adamou, A.; Pectasides, Dimitrios; Economopoulos, T.; Kalofonos, H. P.; Bafaloukos, Dimitrios; Georgoulias, V.; Razi, E. D.; Koukouras, D.; Zombolas, V.; Kosmidis, Paraskevas A.; Skarlos, Dimosthenis V.; Pavlidis, Nicholas (2004)
      The present randomized phase III trial was designed to detect a 15% benefit in relapse-free survival (RFS) or overall survival (OS) from the incorporation of adjuvant tamoxifen to the combination of CNF [cyclophosphamide, ...

    • Article  

      Biweekly administration of 24-h infusion of irinotecan followed by a 1-h infusion of docetaxel: A phase I study 

      Briassoulis, E. Ch; Pentheroudakis, George; Timotheadou, H.; Rammou, D.; Pavlidis, Nicholas; Fountzilas, George (2004)
      We developed a chemotherapy combination regimen based on preclinical data suggesting synchronization of cancer cells in G2/M phase when exposed to irinotecan over a protracted period. This phase I study aimed to determine ...

    • Article  

      CEOP-21 versus CEOP-14 chemotherapy with or without rituximab for the first-line treatment of patients with aggressive lymphomas: Results of the HE22A99 trial of the hellenic cooperative oncology group 

      Economopoulos, T.; Psyrri, A.; Dimopoulos, M. A.; Kalogera-Fountzila, Anna; Pavlidis, Nicholas; Tsatalas, C.; Nikolaides, C.; Mellou, S.; Xiros, N.; Fountzilas, George (2007)
      Background: In this study we investigated whether administering CEOP (cyclophosphamide, epirubicin, vincristine [Oncovin], and prednisone) every 2 weeks (CEOP-14) instead of every 3 weeks (the standard CEOP-21 regimen) ...

    • Article  

      Combination chemotherapy with gemcitabine and vinorelbine in the treatment of relapsed or refractory diffuse large B-cell lymphoma: A phase-II trial by the Hellenic Cooperative Oncology Group 

      Papageorgiou, E.; Tsirigotis, P.; Dimopoulos, M. A.; Pavlidis, Nicholas; Fountzilas, George; Papageorgiou, S.; Economopoulos, T. (2005)
      To investigate the efficacy and toxicity of the combination of gemcitabine and vinorelbine in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBL), 22 patients with relapsed or refractory DLBL were ...

    • Article  

      Combination chemotherapy with low doses of weekly Carboplatin and oral Etoposide in poor risk small cell lung cancer 

      Samantas, E.; Skarlos, Dimosthenis V.; Pectasides, Dimitrios; Nikolaidis, Pavlos; Kalofonos, H. P.; Mylonakis, N.; Vardoulakis, Th; Kosmidis, Paraskevas A.; Pavlidis, Nicholas; Fountzilas, George (1999)
      Sixty patients with poor prognostic features, either with extensive disease (ED) or limited disease (LD) small cell lung cancer (SCLC), were treated on an out-patient basis with Carboplatin 80 mg/m2 weekly for 3 weeks and ...

    • Article  

      Combination regimen with carboplatin, epirubicin and etoposide in metastatic carcinomas of unknown primary site: A Hellenic Co-operative Oncology Group phase II study 

      Briassoulis, E. Ch; Tsavaris, N.; Fountzilas, George; Athanasiades, A.; Kosmidis, Paraskevas A.; Bafaloukos, Dimitrios; Skarlos, Dimosthenis V.; Samantas, E.; Pavlidis, Nicholas (1998)
      The encouraging results that have been reported for cisplatin combination chemotherapy in a minority of patients with cancer of unknown primary (CUP) together with the previously shown equal activity of carboplatin in this ...

    • Article  

      Cyclophosphamide, mitoxantrone, fluorouracil versus conventional CMF as adjuvant treatment in node-positive breast cancer patients 

      Fountzilas, George; Polichronis, A.; Katsohis, C.; Gennatas, Constantinos; Toussis, D.; Skarlos, Dimosthenis V.; Kosmidis, Paraskevas A.; Vassilaros, S.; Semoglou, C.; Giannakakis, T.; Fahantidis, E.; Klouvas, G. D.; Tsavaris, N.; Konstantaras, C.; Makrantonakis, P.; Kolotas, C.; Zamboglou, N.; Tsiliakos, S.; Hainoglou, D.; Mylonakis, N.; Pavlidis, Nicholas (1996)
      362 evaluable node-positive patients with stage II breast cancer were randomized, receiving either 6 cycles of conventional CMF or 6 cycles of the combination of cyclophosphamide (500 mg/m2), mitoxantrone (Novantrone 10 ...

    • Article  

      Docetaxel (Taxotere™) is active in non-small-cell lung cancer: A phase II trial of the EORTC early clinical trials group (ECTG) 

      Cerny, T.; Kaplan, S.; Pavlidis, Nicholas; Schöffski, P.; Epelbaum, R.; Meerbeek, J. van; Wanders, J.; Franklin, H. R.; Kaye, Stanley B. (1994)
      In a multicentre trial of the EORTC ECTG we have treated 43 non-pretreated patients with advanced non-small-cell lung cancer (NSCLC) with the new semisynthetic taxoid docetaxel (Taxotere). Six patients were ineligible; of ...

    • Article  

      Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: First report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial 

      Fountzilas, George; Dafni, U.; Papadimitriou, C.; Timotheadou, E.; Gogas, H.; Eleftheraki, A. G.; Xanthakis, I.; Christodoulou, C.; Koutras, A. K.; Papandreou, C. N.; Papakostas, P.; Miliaras, S.; Markopoulos, C.; Dimitrakakis, C.; Korantzopoulos, Panagiotis; Karanikiotis, C.; Bafaloukos, Dimitrios; Kosmidis, Paraskevas A.; Samantas, E.; Varthalitis, I.; Pavlidis, Nicholas; Pectasides, Dimitrios; Dimopoulos, M. A. (2014)
      Background: Dose-dense sequential chemotherapy including anthracyclines and taxanes has been established in the adjuvant setting of high-risk operable breast cancer. However, the preferable taxane and optimal schedule of ...

    • Article  

      Dose-dense sequential adjuvant chemotherapy with epirubicin, paclitaxel and CMF in high-risk breast cancer 

      Fountzilas, George; Papadimitriou, C.; Aravantinos, Gerasimos; Nikolaides, C.; Stathopoulos, G. P.; Bafaloukos, Dimitrios; Kalofonos, H. P.; Economopoulos, T.; Skarlos, Dimosthenis V.; Pavlidis, Nicholas; Dimopoulos, M. A. (2001)
      Dose-dense sequential chemotherapy appears to be a promising approach in the management of patients with operable breast cancer. We evaluated the tolerability of such a novel chemotherapeutic regimen in high-risk patients. ...

    • Article  

      Dose-ranging study of metronomic oral vinorelbine in patients with advanced refractory cancer 

      Briassoulis, E. Ch; Pappas, P.; Puozzo, C.; Ch, F. Tolis; Fountzilas, George; Dafni, U.; Marselos, M.; Pavlidis, Nicholas (2009)
      Aim: To determine the safe dose range and pharmacokinetics of metronomic oral vinorelbine and obtain preliminary data on biomarkers and efficacy in patients with advanced cancer. Methods: Successive cohorts ofpatients ...

    • Article  

      Feasibility study and pharmacokinetics of low-dose paclitaxel in cancer patients with severe hepatic dysfunction 

      Briassoulis, E. Ch; Karavasilis, V.; Tzamakou, E.; Piperidou, C.; Soulti, K.; Pavlidis, Nicholas (2006)
      The aim of this study is to investigate the feasibility and determine the pharmacokinetics of low-dose paclitaxel in cancer patients with severe hepatic dysfunction. This was a prospective study. Patients with liver ...

    • Article  

      Gemcitabine plus pegylated liposomal doxorubicin in patients with advanced epithelial ovarian cancer resistant/refractory to platinum and/or taxanes. A HeCOG phase II study 

      Skarlos, Dimosthenis V.; Kalofonos, H. P.; Fountzilas, George; Dimopoulos, M. A.; Pavlidis, Nicholas; Razi, E. D.; Economopoulos, T.; Pectasides, Dimitrios; Gogas, H.; Kosmidis, Paraskevas A.; Bafaloukos, Dimitrios; Klouvas, G. D.; Kyratzis, G.; Aravantinos, Gerasimos (2005)
      Background: A phase II study was conducted to evaluate the efficacy and toxicity of the combination of gemcitabine (GEM) and pegylated liposomal doxorubicin (PLD) in patients with platinum- and/or taxane-resistant/refractory ...

    • Article  

      Glufosfamide administered using a 1-hour infusion given as first-line treatment for advanced pancreatic cancer. A phase II trial of the EORTC-new drug development group 

      Briassoulis, E. Ch; Pavlidis, Nicholas; Terret, C.; Bauer, J.; Fiedler, W.; Schöffski, P.; Raoul, J. L.; Hess, D.; Selvais, R.; Lacombe, D.; Bachmann, P.; Fumoleau, P. (2003)
      The activity of glufosfamide (β-D-glucopyranosyl-N,N′ -di-(2-chloroethyl)-phosphoric acid diamide) against pancreatic cancer was investigated in a multicentre, phase II clinical study. Chemotherapy-naïve patients with ...

    • Article  

      High‐dose epirubicin and r‐met‐hu G‐CSF (Filgrastim) in the treatment of patients with advanced breast cancer: A hellenic cooperative oncology group study 

      Fountzilas, George; Skarlos, Dimosthenis V.; Katsohis, C.; Pavlidis, Nicholas; Giannakakis, T.; Bafaloukos, Dimitrios; Fahantidis, E.; Klouvas, G. D.; Beer, M.; Kosmidis, Paraskevas A. (1995)
      The delivery of high‐dose epirubicin in patients with advanced breast cancer usually entails serious myelotoxicity and frequent treatment delays. Concurrent administration of G‐CSF probably allows the administration of ...

    • Article  

      Ifosfamide plus oral etoposide salvage chemotherapy for platinum- resistant paclitaxel-pretreated ovarian cancer 

      Aravantinos, Gerasimos; Dimopoulos, M. A.; Kosmidis, Paraskevas A.; Bafaloukos, Dimitrios; Papadimitriou, C.; Kiamouris, Ch; Pavlidis, Nicholas; Sikiotis, K.; Papakostas, P.; Skarlos, Dimosthenis V. (2000)
      Background: The prognosis of platinum resistant ovarian cancer is very poor and the treatment of choice has not been clearly defined. Patients and methods: We conducted a phase II study with the combination of ifosfamide ...

    • Article  

      Integrating trastuzumab in the neoadjuvant treatment of primary breast cancer: Accumulating evidence of efficacy, synergy and safety 

      Lazaridis, G.; Pentheroudakis, George; Pavlidis, Nicholas (2008)
      Neoadjuvant chemotherapy is used in non-metastatic breast cancer in order to eradicate micrometastatic deposits early during disease course, as well as in order to decrease tumour bulk and render surgery feasible or ...

    • Article  

      Mitoxantrone (novantrone*) as single agent and in combination chemotherapy in the treatment of advanced breast cancer 

      Smith, I. E.; Stuart-Harris, R. C.; Pavlidis, Nicholas; Bozek, T. (1983)
      Nineteen out of 62 evaluable patients with advanced breast cancer achieved an objective tumour response to mitoxantrone (31%) given in a dose of 12-14 mg/m2 by i.v. infusion repeated at 3-weekly intervals. The response ...

    • Article  

      Mitoxantrone: An active new agent in the treatment of advanced breast cancer 

      Stuart-Harris, R. C.; Bozek, T.; Pavlidis, Nicholas; Smith, I. E. (1984)
      Sixty-five patients with advanced breast carcinoma were treated with mitoxantrone, an anthracenedione with structural similarities to adriamycin. The series included 26 patients who had received no prior chemotherapy. ...

      Browse

      EverywhereCommunities & CollectionsBy Submission DateAuthorsTitlesSubjectsBy TypeBy DepartmentBy Faculty

      My Account

      Login
      Πνευματικά δικαιώματα ©  Βιβλιοθήκη Πανεπιστημίου Κύπρου
      Contact Us | Send Feedback
      Οδηγίες κατάθεσης διδακτορικής διατριβής
      Open Access
      ORCiD